Building foundation models that transform scientific data into actionable discovery.
Get in TouchAethron Labs is an independent research lab focused on developing large-scale machine learning systems for interpreting complex scientific data. Our work is centered on building foundational capabilities rather than narrow tools or application-specific models.
What We've Built
Foundation & Data
Model Architecture
Commercial Execution
Across the life sciences and molecular research, data generation has dramatically outpaced our ability to interpret it. Core analytical technologies produce enormous volumes of rich, high-dimensional measurements, yet downstream understanding still depends on fragile heuristics, limited reference data, and manual analysis.
This gap constrains discovery, slows research, and limits what can be reliably inferred from experimental data.
We believe this is fundamentally a representation problem. Aethron Labs is building foundation models that learn directly from raw scientific data, capturing underlying structure in a way that generalizes across instruments, conditions, and experimental settings.
The goal is not to replace existing workflows, but to create a new computational substrate that makes scientific interpretation more scalable, reliable, and extensible.
Note: Aethron Labs is currently in the development phase. The market projections below are based on preliminary market research and industry analysis.
$200B
Global pharmaceutical R&D spend annually
$90B
Global CRO market size annually
$50B+
Addressable analytical services market
This spend is recurring, operational, and directly tied to throughput and turnaround time.
Mid-to-large CROs typically operate 10s-100s of LC-MS/MS instruments processing millions of spectra per year, with teams of analysts whose time is the primary cost driver.
30-50%
Reduction in manual interpretation time
10-100+
Instruments per large CRO
1M+
Spectra analyzed annually
Initial commercialization targets enterprise API licensing for programmatic molecular search and analysis, priced against analyst time and throughput rather than per-sample novelty.
This supports a credible $50-200M serviceable obtainable market before broader expansion.
Simple and Credible
The initial GTM is intentionally narrow and execution-driven.
Aethron Labs targets CROs first, not broad enterprise rollouts. CROs feel the MS/MS bottleneck most acutely: turnaround time, analyst throughput, and defensibility of results directly determine their margins and competitiveness.
This turns latent demand into evidence. The goal is not rapid scaling at first, but credible proof that this infrastructure works in real workflows.
What begins as programmatic molecular search for LC-MS/MS expands as models and representations mature:
Used across drug discovery, DMPK, metabolomics, and materials research.
Becomes a standard interpretation layer rather than a standalone tool.
A reusable computational substrate for molecular science, materials science, and other data-intensive physical sciences.
TAM expands to multiple tens of billions across research, instrumentation, and discovery workflows.
At this stage, the opportunity expands from tooling budgets to core scientific computing infrastructure.
Founder: Allan
5 years total experience in ML and scientific computing
3 years in open-source development and research:
2 years industry experience:
This background spans the full stack required for this problem: scientific domain understanding, large-scale ML systems, and production engineering realities.
Aethron Labs is structured to reflect this combination from day one.
This effort is motivated by a rare convergence:
The opportunity is not incremental optimization. It is to define a new category of scientific infrastructure that sits between raw experimental data and downstream discovery.
By starting with a concrete, economically grounded use case (CRO workflows) and expanding deliberately, Aethron Labs aims to:
This is a long-term bet on advancing science as a system, not just improving a workflow.
If you work in scientific research, analytical chemistry, pharma, or scientific machine learning, and are interested in exchanging perspectives, I welcome the conversation.
Get in Touch